Meric-Bernstam, F., Beeram, M., Hamilton, E., Oh, D., Hanna, D. L., Kang, Y., Elimova, E., Chaves, J., Goodwin, R., Lee, J., Nabell, L., Rha, S. Y., Mayordomo, J., El-Khoueiry, A., Pant, S., Raghav, K., Kim, J. W., Patnaik, A., Gray, T., Davies, R., Ozog, M. A., Woolery, J., & Lee, K. (2022). zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study. Lancet oncology, 23(12), 1558–1570. http://access.bl.uk/ark:/81055/vdc_100170506791.0x000027